ENGN enGene Therapeutics Inc.
Distress ·
enGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand.
The bladder cancer gene therapy developer stopped enrollment in three study cohorts to conserve cash. It plans to start its BLA filing in the second half of 2026.
The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold.
The Second Amendment draws $25 million at closing to refinance existing term loans. Further tranches depend on milestones.
| Line | FY ended Oct 31, 2025 | FY ended Oct 31, 2024 |
|---|---|---|
| Research and development | $94.5 million | $38.3 million |
| Net income (loss) | -$117.3 million | -$55.1 million |
| Cash from operations | -$99.2 million | -$48.3 million |
| Cash and equivalents | $50.2 million | $173.0 million |
| Short-term investments | $143.6 million | $65.3 million |
enGene Therapeutics Inc. trades under the ticker ENGN on NASDAQ.
enGene Therapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for enGene Therapeutics Inc. is 1980845. Its filings are on SEC EDGAR.
67,016,316 shares as of 2026-09-02, per the cover page of its 10-Q filed 2026-09-08.
Our directory records enGene Therapeutics Inc. under Canada.
Our directory classifies enGene Therapeutics Inc. as: Non-viral genetic medicines. This is a directory classification, not a description of the pipeline.
The ISIN recorded for enGene Therapeutics Inc. is CA29286X1015.
aibio.space lists enGene Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as Z4.
enGene Therapeutics Inc. reported a net loss of $117.3 million for the fiscal year ended Oct 31, 2025, and used $99.2 million of cash in operations, per its annual report to the SEC.
$94.5 million in the fiscal year ended Oct 31, 2025, per its annual report.
$266.3 million in cash and short-term investments at Jul 31, 2026, per its 10-Q.
Our latest story on enGene Therapeutics, dated Jun 15, 2026: "enGene Therapeutics cuts workforce by about 50% in restructuring to preserve cash". enGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand. Source.
Our latest financing story, dated Mar 9, 2026: "enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program". The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold. Source.
From our story: Leerink is the sales agent and may sell by any method that counts as an at-the-market offering under the securities rules, or by any other method the law permits. Source.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio